单侧肾上腺偶发瘤伴轻度自主皮质醇分泌患者手术治疗动脉性高血压(CHIRACIC):多中心、开放标签、优效性随机对照试验
CHIRACIC 研究在法国、意大利、德国17所大学医院纳入52例单侧肾上腺偶发瘤伴轻度自主皮质醇分泌(MACS)的高血压患者,随机分至肾上腺切除术或保守治疗。研究完成时,肾上腺切除组家庭血压正常且降压治疗减量的比例为46%(12/26),保守组为15%(4/26),校正风险差0.34(95%CI 0.11~0.58;p=0.0038)。
要点
- 肾上腺切除组46%(12/26)实现家庭血压正常且降压治疗减量,保守组为15%(4/26),校正风险差0.34(95%CI 0.11~0.58;p=0.0038)。
- 研究完成时仍需降压治疗者:肾上腺切除组10/23(43%),保守组24/25(96%),校正风险差-0.58(95%CI -0.78~-0.38;p<0.0001)。
- 平均降压治疗步骤:肾上腺切除组0.8(SD 1.1)vs 保守组3.0(1.4),校正差值-2.05(95%CI -2.61~-1.50;p<0.0001)。
核心结论
- 单侧肾上腺偶发瘤相关的MACS可导致继发性高血压,微创肾上腺切除术可安全地改善该高血压。
研究设计与样本
- CHIRACIC为在法国、意大利和德国17所大学医院开展的多中心、优效性、开放标签、平行随机对照试验。
- 78例患者入组,52例符合条件者按1:1随机分配至肾上腺切除术(n=26,其中23例接受手术并完成研究)或保守治疗(n=26,其中25例完成研究)。
- 随机分组采用区组随机(随机区组大小4和6),并按降压治疗强度分层;随访13个月,并系统尝试逐步减少降压治疗。
- 主要终点为研究完成时意向性治疗人群中,家庭血压监测(HBPM)下血压正常且降压治疗减量的参与者比例。
主要发现
- 研究完成时,肾上腺切除组12/26(46%)实现家庭血压正常且降压治疗减量,保守组4/26(15%),校正风险差0.34(95%CI 0.11~0.58;p=0.0038)。
- 24小时动态血压监测(ABPM)收缩压观察到相似但幅度较小的结果。
- 研究完成时仍需降压治疗者:肾上腺切除组10/23(43%)vs 保守组24/25(96%),校正风险差-0.58(95%CI -0.78~-0.38;p<0.0001)。
- 平均降压治疗步骤:肾上腺切除组0.8(SD 1.1)vs 保守组3.0(1.4),校正差值-2.05(95%CI -2.61~-1.50;p<0.0001)。
- 家庭收缩压正常且未用降压治疗的患者数:肾上腺切除组12/23(52%),保守组0例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adrenal incidentalomas are found in 3-10% of adults undergoing abdominal imaging. Of these, 30-50% are responsible for mild autonomous cortisol secretion (MACS), which is frequently associated with hypertension. The impact of adrenalectomy on hypertension in patients with unilateral incidentalomas and MACS remains uncertain. The aim of the CHIRACIC study was to prospectively assess the impact of surgical excision of the incidentaloma on blood pressure with a randomised trial combining accurate blood pressure measurement and standardisation of antihypertensive treatment. METHODS: CHIRACIC was a multicentre, superiority, open-label, parallel, randomised controlled trial performed at 17 university hospitals in France, Italy, and Germany. Adults with hypertension with MACS entered a run-in phase to confirm hypertension with multiple home blood pressure measurements (HBPM) before blood pressure was normalised with standardised stepped-care antihypertensive treatment. Eligible participants were then randomly assigned (1:1) to adrenalectomy or conservative management. Randomisation was blocked (random block size of 4 and 6) and stratified by intensity of antihypertensive treatment. Participants were followed up for 13 months and systematic attempts were made to gradually reduce antihypertensive treatment. The primary endpoint was the proportion of normotensive participants using HBPM who reduced their antihypertensive treatment in the intention-to-treat population at study completion. Key secondary endpoints included 24 h ambulatory blood pressure measurement (ABPM), mean change in antihypertensive treatment, and the proportion of participants with antihypertensive treatment at study completion. This study was registered with ClinicalTrials.gov, NCT02364089, and is completed. FINDINGS: Between April 9, 2015 and Nov 23, 2022, 78 patients were enrolled, and 52 eligible participants were randomly assigned to adrenalectomy (n=26, 23 underwent adrenalectomy and completed the study) or conservative management (n=26, 25 completed the study). The median age of participants was 63·3 years (IQR 57·4-68·2) and 36 (69%) were female. At study completion, a reduction in antihypertensive treatment with normal HBPM was observed in 12 (46%) of 26 participants treated with adrenalectomy and in four (15%) of 26 treated conservatively (adjusted risk difference [RD] 0·34 [95% CI 0·11 to 0·58]; p=0·0038). Similar results of smaller magnitude were observed for systolic blood pressure during 24 h ABPM. There were ten (43%) of 23 participants still needing antihypertensive treatment in the adrenalectomy group and 24 (96%) of 25 in the conservative management group (adjusted RD -0·58 [95% CI -0·78 to -0·38]; p<0·0001). Mean antihypertensive treatment step was 0·8 (SD 1·1) in the adrenalectomy group and 3·0 (1·4) in the conservative management groups (adjusted difference -2·05 [95% CI -2·61 to -1·50]; p<0·0001]. The number of patients with normal systolic HBPM and no hypertensive treatment was 12 (52%) of 23 in the adrenalectomy group and none in the conservative management group. Serious adverse events occurred in eight (35%) of 23 participants in the adrenalectomy group and eight (31%) of 26 participants in the conservative management group. Three serious adverse events for three (13%) participants were related to the surgery (post-surgical wall pain and hypotension). INTERPRETATION: MACS associated with unilateral adrenal incidentalomas is responsible for secondary hypertension that can be safely improved by minimally-invasive adrenalectomy. FUNDING: French Ministry of Health and the German Research Foundation.
引用
- Tabarin A, Espiard S, Deutschbein T, et al. Surgery for the treatment of arterial hypertension in patients with unilateral adrenal incidentalomas and mild autonomous cortisol secretion (CHIRACIC): a multicentre, open-label, superiority randomised controlled trial. Lancet Diabetes Endocrinol. 2025. PMID: 40373786. doi:10.1016/S2213-8587(25)00062-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。